Skip to main content

TransMedics Group, Inc.

For the period ended Jun 30, 2025. Filed Jul 30, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Jul 30, 2025

TMDX$90.95-3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Cash Flows

(In thousands)

Six Months Ended June 30,
20252024
Cash flows from operating activities:
Net income$60,589$24,391
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization expense12,8688,901
Stock-based compensation expense18,33014,513
Non-cash interest expense and end of term accretion expense1,5781,547
Non-cash lease expense997650
Unrealized foreign currency transaction (gains) losses(1,473)200
Loss on disposal of fixed assets80—
Changes in operating assets and liabilities
Accounts receivable(6,616)(17,650)
Inventory5,717(7,932)
Prepaid expenses and other current assets1,081(3,217)
Other non-current assets(4)(24)
Accounts payable(410)1,778
Accrued expenses and other current liabilities(2,413)630
Deferred revenue(192)(504)
Operating lease liabilities(1,378)(1,000)
Net cash provided by operating activities88,75422,283
Cash flows from investing activities:
Purchases of property, plant and equipment(36,113)(67,935)
Net cash used in investing activities(36,113)(67,935)
Cash flows from financing activities:
Proceeds from issuance of common stock upon exercise of stock options8,83113,188
Proceeds from issuance of common stock in connection with employee stock purchase plan1,286638
Net cash provided by financing activities10,11713,826
Effect of exchange rate changes on cash and restricted cash1,167(235)
Net increase (decrease) in cash and restricted cash63,925(32,061)
Cash and restricted cash, beginning of period337,150395,312
Cash and restricted cash, end of period$401,075$363,251
Supplemental disclosure of non-cash activities:
Transfers of inventory to property, plant and equipment$2,251$3,381
Purchases of property, plant and equipment included in accounts payable and accrued expenses$1,240$1,540
Operating lease liabilities arising from obtaining right-of-use assets$324$—
Reconciliation of cash and restricted cash:
Cash$400,575$362,751
Restricted cash500500
Total cash and restricted cash shown in the statement of cash flows$401,075$363,251
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.